Abstract
Objective. To determine whether intravenous (IV) metoclopramide 20mg + diphenhydramine 25mg (M+D) was more efficacious than IV placebo for acute moderate or severe post-traumatic headache in the emergency room.
Methods. We conducted this randomized, double blind, placebo controlled, parallel group study in two urban emergency departments (ED). Participants who experienced head trauma and presented to our EDs within 10 days with a headache fulfilling criteria for acute post-traumatic headache were included. We randomized participants in a 1:1 ratio to M+D or placebo. Participants, care givers, and outcome assessors were blinded to assignment. The primary outcome was improvement in pain on a 0-10 scale between baseline and one hour post treatment.
Results. This study was completed between August 2017 and March 2020.We screened 414 patients for participation and randomized 160, 81 to M+D and 79 to placebo. Baseline characteristics were comparable between the groups. All enrolled participants provided primary outcome data. Placebo patients reported mean improvement of 3.8 (SD 2.6) while M+D improved by 5.2 (SD 2.3), for a difference favoring metoclopramide of 1.4 (95% CI 0.7, 2.2, p<0.01). Adverse events were reported by 35/81 (43%) of patients who received metoclopramide and 22/79 (28%) of patients who received placebo (95% CI for difference of 15%: 1, 30%, p=0.04).
Conclusion. Metoclopramide + diphenhydramine was more efficacious than placebo with regard to relief of post-traumatic headache in the ED.
Classification of evidence: This study provides Class I evidence that for patients with acute moderate or severe post-traumatic headache, IV metoclopramide + diphenhydramine significantly improved pain compared to placebo.
- Received July 13, 2020.
- Accepted in final form February 2, 2021.
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.